Agios Pharma CLO Gets $200K in Performance Shares, Sells Portion for Taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
James William Burns, Chief Legal Officer of Agios Pharmaceuticals (AGIO), reported significant insider transactions on June 24, 2025:
- Acquired 6,000 shares through the vesting of Performance Share Units (PSUs) at $0 exercise price
- Subsequently sold 2,799 shares at $33.54 per share to cover tax withholding obligations
- Following these transactions, Burns now directly owns 28,650 shares
The PSUs were originally granted on March 1, 2023, with 50% vesting upon achievement of a research milestone and 50% upon a regulatory milestone. The reported transaction reflects the vesting of the first 50% as the research milestone was met. The share sale was executed under a pre-established Rule 10b5-1 trading plan, providing an affirmative defense against insider trading liability.
Positive
- Performance milestone achievement: Company met specified research milestone, triggering 50% vesting of PSUs, indicating successful R&D progress
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance share units | 6,000 | $0.00 | $0.00 |
| Exercise | Common stock | 6,000 | $0.00 | $0.00 |
| Sale | Common stock | 2,799 | $33.54 | $94K |
Footnotes (3)
- F1. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023.
- F2. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- F3. The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider trading activity occurred at AGIO on June 24, 2025?
Was AGIO's insider sale conducted under Rule 10b5-1?
AI-generated analysis. How Rhea-AI works. Not financial advice.